Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL9398356 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL9398351 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL2847926 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL29437926 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL5312626 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL33348 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL3854638 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145268 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL8184989 | 0.99 | CYP3A4 (0.98) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145267 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138523-B2 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC. (CA) | 2006-11-21 | — | — | US | claimed |
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC (CA) | 2003-11-27 | — | — | US | claimed |
| US-7138523-B2 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC. (CA) | 2006-11-21 | — | — | US | disclosed |
| EP-1384720-A1 | Process for drying paroxetine hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003097599-A1 | PREPARATION OF 4-(4-FLUOROPHENYL)-N-SUBSTITUTEDNIPECOTINATE ESTERS | APOTEX PHARMACHEM INC. (CA) | 2003-11-27 | — | — | WO | disclosed |
| US-5973155-A | Process for preparing (-)-trans-N-p-fluorobenzoylmethyl-4-(p-fluorophenyl)-3-[[3,4-(methylened ioxy)phenoxy]methyl]-piperidine | FERRER INTERNACIONAL, S.A. (ES) | 1999-10-26 | — | — | US | disclosed |
| EP-0699198-B1 | N-BENZOYLMETHYL SUBSTITUTED PAROXETINE DERIVATIVES | FERRER INT (ES) | 1999-06-30 | — | — | EP | disclosed |
| EP-0823907-B1 | PROCESS FOR PREPARING (-)-TRANS-N-p-FLUOROBENZOYLMETHYL-4-(p-FLUOROPHENYL)-3-[[3,4-(METHYLENEDIOXY)PHENOXY]METHYL]-PIPERIDINE | FERRER INT (ES) | 1999-05-26 | — | — | EP | disclosed |
| EP-0339579-B1 | Piperidine compositions and their preparation and use | NOVO NORDISK AS (DK) | 1998-07-15 | — | — | EP | disclosed |
| EP-0828735-A1 | PROCESS FOR PREPARING 4-ARYL-PIPERIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-03-18 | — | — | EP | disclosed |
| US-5227379-A | 1-Heterocycyl-4-phenyl substituted, calcium-channel antagonists | NOVO NORDISK A/S (DK) | 1993-07-13 | — | — | US | disclosed |
| US-5208232-A | Anoxia, migraine; antiepileptic and antiischemic agents | NOVO NORDISK A/S (DK) | 1993-05-04 | — | — | US | disclosed |
| US-5158961-A | Treatment of anoxia, migraine, ischemica and epilepsy | NOVO NORDISK A/S (DK) | 1992-10-27 | — | — | US | disclosed |
| US-5019582-A | Preventing Calcium Overload In Brain Cells | NOVO NORDISK A/S (DK) | 1991-05-28 | — | — | US | disclosed |
| US-5017585-A | Piperidine compounds | NOVO NORDISK A/S (DK) | 1991-05-21 | — | — | US | disclosed |
| US-4985446-A | CALCIUM OVERLOAD BLOCKERS IN BRAIN CELLS | A/S FERROSAN (DK) | 1991-01-15 | — | — | US | disclosed |
| US-4877799-A | Method of treating calcium overload in brain cells of mammals | A/S FERROSAN (DK) | 1989-10-31 | — | — | US | disclosed |
| EP-0266574-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1988-05-11 | — | — | EP | disclosed |
| EP-0223403-A2 | Piperidine derivative, its preparation, and its use as medicament | BEECHAM GROUP PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | PFAS, B3GNT2, APRT | SLC6A4 594/4885CYP3A4 272/4885MEN1 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.